ViroGates A/S
VIRO
Rank in Stocks
#28364
ViroGates A/S is a Danish firm specializing in the creation and... ViroGates A/S is a Danish firm specializing in the creation and commercialization of prognostic diagnostic solutions for the medical field. Its flagship product, suPARnostic, is a blood test designed to quantify the soluble urokinase plasminogen activator receptor (suPAR) protein within a patient's circulatory system. This innovative tool empowers hospital emergency rooms to refine their clinical assessments regarding the admission or release of patients with acute medical conditions, thereby contributing to lower healthcare expenditures. Beyond this, ViroGates also supplies several other suPARnostic variations: suPARnostic TurbiLatex, a specialized latex particle-enhanced turbidimetric immunoassay for precise suPAR quantification in specific human plasma samples (K2-EDTA or lithium heparin); the suPARnostic Quick Triage kit, optimized for rapid early warning and patient categorization at the point of care; and suPARnostic ELISA, which delivers comprehensive quantitative readings. The prognostic capabilities of suPAR extend across a broad spectrum of medical conditions, encompassing cardiovascular, renal, oncological, diabetic, hepatic, infectious, respiratory, and rheumatic diseases. Established in 2000, the company maintains its headquarters in Birkerød, Denmark.
Share Price
$1.24
Last synced: 2026-11-09
Market Cap
$11.27M
Change (1 day)
6.47%
Change (1 year)
-38.15%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade ViroGates A/S (VIRO)
Category
Healthcare
EPS for ViroGates A/S (VIRO)
EPS as of June 2026 TTM: $-0.13
According to ViroGates A/S's latest financial reports, its current EPS (TTM) is $-0.13. At the end of 2025 the company had an EPS of $-0.21, an increase over its 2024 EPS of $-0.30.
EPS history for ViroGates A/S from 2015 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.13 | -37.48% |
| 2025 | $-0.21 | -30.90% |
| 2024 | $-0.30 | -41.94% |
| 2023 | $-0.52 | 56.77% |
| 2022 | $-0.33 | -50.11% |
| 2021 | $-0.66 | -14.20% |
| 2020 | $-0.77 | 7.32% |
| 2019 | $-0.72 | -18.48% |
| 2018 | $-0.88 | 101.51% |
| 2017 | $-0.44 | 63.68% |
| 2016 | $-0.27 | 28.95% |
| 2015 | $-0.21 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $2.70 | -2,156.36% |
US
|
|
| $4.09 | -3,215.00% |
IE
|
|
| $9.45 | -7,297.26% |
US
|
|
| $2.37 | -1,905.03% |
US
|
|
| $1.77 | -1,448.06% |
US
|
Questions about ViroGates A/S's earnings per share (EPS)
What is ViroGates A/S's earnings per share (EPS)?
ViroGates A/S's earnings per share (EPS) over the last twelve months is $-0.13, as of Jun 2026.
What was ViroGates A/S's earnings per share (EPS) in 2025?
In 2025, ViroGates A/S's earnings per share (EPS) was $-0.21, compared with $-0.30 in 2024.
How has ViroGates A/S's earnings per share (EPS) changed since 2020?
From 2020 to 2025, ViroGates A/S's earnings per share (EPS) was highest in 2025 ($-0.21) and lowest in 2020 ($-0.77).
How does ViroGates A/S's earnings per share (EPS) compare with similar companies?
ViroGates A/S's earnings per share (EPS) ($-0.13) is lower than that of all 5 similar companies listed above. The highest among them is Stryker Corporation, with $9.45.